Diagnostics – Aus/NZ, Canada, Ireland
Diploma Healthcare Group is proud of our innovative suppliers who offer patients cutting edge diagnostic solutions. With operations throughout Canada, Australia, and the UK, DHG works with hospitals and laboratories to ensure that the best possible solutions are available to meet their diagnostic and operational needs. We currently have a strong presence and focus in Theranostics, CRC Screening and HbA1c measurement in addition to multiple specialties throughout the diagnostics spectrum.
HbA1c (hemoglobin A1c) measurement is a common tool for the diagnosis of diabetes. DHG has strong partnerships with industry leading HbA1c testing suppliers who offer systems to ensure rapid automated diabetes diagnosis, through high resolution capillary separation technology. The devices represented by DHG offer precise separation of hemoglobin fractions with accurate HbA1c measurement without interference.
We understand the growing demand for efficient, complete, and accurate, technologies that benefit both the patient and those administrating the tests. For example, DHG partners with a supplier who offers a wide range of traditional allergen tests in addition to the newest purified allergen components. These purified allergen components allow for enhanced allergy diagnosis by pinpointing which component a patient is sensitized to at the exact molecular level. In addition to those tests, DHG also works to offer automated in-vitro allergy testing.
With cancer affecting more and more families across the globe, DHG wants to offer a fighting chance to patients through a variety of approaches. Two key methodologies include, Colorectal Cancer Screening with Fecal Immunochemical Testing (FIT) and Theranostics. Fecal Immunochemical Testing requires only one sample with results that provide the highest sensitivity and specificity in the industry. Using FIT allows for earlier detection and less un-necessary colonoscopies. Theranostics is the measurement of a patient’s response to anti-tumor necrosis factor (anti-TNFα) drugs such as Inflixmab and Adalimumab. Some patients experience a poor response to these drugs. By measuring the levels of prescribed drugs clinicians may now provide a customized treatment plan for their patients.
Whether testing for routine allergens or improving the fight against cancer, Diploma Healthcare Group has the most state-of-the-art diagnostic solutions.